GAVRETO Now approved

Introducing GAVRETO™, the only once-daily targeted RET therapy for patients with RET fusion+ metastatic NSCLC.1

NSCLC=non–small cell lung cancer; RET=rearranged during transfection.

NSCLC=non–small cell lung cancer; RET=rearranged during transfection.